{"id":"peg-400-based-artificial-tear","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Polyethylene glycol (PEG-400) is a hydrophilic polymer that acts as a lubricant and demulcent on the corneal and conjunctival surfaces. It increases tear film viscosity and stability, reducing evaporation and providing prolonged ocular surface hydration. This mechanism alleviates symptoms of dry eye disease by maintaining a stable tear film and protecting the epithelium from desiccation.","oneSentence":"PEG-400 based artificial tear lubricates and protects the ocular surface by forming a protective film that retains moisture and reduces friction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:11.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease / Keratoconjunctivitis sicca"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30},{"nctId":"NCT05028907","phase":"PHASE4","title":"Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis","status":"COMPLETED","sponsor":"Sohag University","startDate":"2020-11-15","conditions":"Ophthalmopathy , Lacrimal System","enrollment":64},{"nctId":"NCT03706443","phase":"NA","title":"Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2018-12-05","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases","enrollment":24},{"nctId":"NCT02516202","phase":"PHASE3","title":"The Vaginal Health Trial","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-04","conditions":"Atrophy of Vagina, Menopause, Dyspareunia (Female)","enrollment":302},{"nctId":"NCT01924091","phase":"PHASE1","title":"PK/PD of Single Dose Dapivirine Vaginal Film","status":"COMPLETED","sponsor":"International Partnership for Microbicides, Inc.","startDate":"2013-09","conditions":"Pharmaokinetics","enrollment":60},{"nctId":"NCT01576354","phase":"PHASE2","title":"Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2012-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT00932477","phase":"NA","title":"Safety and Tolerability of Artificial Tears in Dry Eye Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Dry Eye Syndrome","enrollment":47},{"nctId":"NCT01010282","phase":"NA","title":"Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Dry Eye Syndrome","enrollment":288},{"nctId":"NCT00622037","phase":"PHASE4","title":"Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-02","conditions":"Dry Eye","enrollment":70},{"nctId":"NCT00620893","phase":"PHASE4","title":"Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-02","conditions":"Dry Eye Syndromes","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PEG- 400 based artificial tear","genericName":"PEG- 400 based artificial tear","companyName":"Bp Consulting, Inc","companyId":"bp-consulting-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-400 based artificial tear lubricates and protects the ocular surface by forming a protective film that retains moisture and reduces friction. Used for Dry eye disease / Keratoconjunctivitis sicca.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}